These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 19780711)

  • 1. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
    Abu Lila AS; Ishida T; Kiwada H
    Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
    Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
    J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and development of polymer conjugates as anti-angiogenic agents.
    Segal E; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
    Bouzin C; Feron O
    Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor.
    Abu Lila AS; Doi Y; Nakamura K; Ishida T; Kiwada H
    J Control Release; 2010 Mar; 142(2):167-73. PubMed ID: 19861140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting anticancer drugs to tumor vasculature using cationic liposomes.
    Abu Lila AS; Ishida T; Kiwada H
    Pharm Res; 2010 Jul; 27(7):1171-83. PubMed ID: 20333455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of the tumor vasculature.
    Tozer GM; Bicknell R
    Semin Radiat Oncol; 2004 Jul; 14(3):222-32. PubMed ID: 15254865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel agents target existing tumor vasculature.
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):303. PubMed ID: 20235388
    [No Abstract]   [Full Text] [Related]  

  • 9. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells.
    Schiffelers RM; Storm G
    Int J Pharm; 2008 Dec; 364(2):258-64. PubMed ID: 18773947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liposome-mediated therapy of neuroblastoma.
    Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
    Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel angiogenesis inhibitors for molecular target therapy of cancer].
    Osada H; Kakeya H
    Nihon Rinsho; 2004 Jul; 62(7):1257-63. PubMed ID: 15283141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy: Back to the future!
    André N; Padovani L; Verschuur A
    Drug News Perspect; 2010 Mar; 23(2):143-51. PubMed ID: 20369080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
    van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
    Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal cancer therapy: exploiting tumor characteristics.
    Kaasgaard T; Andresen TL
    Expert Opin Drug Deliv; 2010 Feb; 7(2):225-43. PubMed ID: 20095944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the tumor vascular compartment to improve conventional cancer therapy.
    Feron O
    Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics.
    Campbell RB; Ying B; Kuesters GM; Hemphill R
    J Pharm Sci; 2009 Feb; 98(2):411-29. PubMed ID: 18563780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
    Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
    Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular damaging agents.
    Patterson DM; Rustin GJ
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):443-56. PubMed ID: 17459681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
    Kim JY; Shim G; Choi HW; Park J; Chung SW; Kim S; Kim K; Kwon IC; Kim CW; Kim SY; Yang VC; Oh YK; Byun Y
    Biomaterials; 2012 Jun; 33(17):4424-30. PubMed ID: 22425551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor vasculature as target for therapeutic intervention.
    Fens MH; Storm G; Schiffelers RM
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1321-38. PubMed ID: 20946091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.